4.09% -0.0347

Biofrontera Inc (BFRI)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Biofrontera Inc Stock (BFRI) Company Profile

Biofrontera Inc

Healthcare (1167)

781-245-1325

120 PRESIDENTIAL WAY,, WOBURN

Nächster Verdiensttermin

Neueste SEC-Einreichungen

BFRI's Discussions on Twitter

Vergleichen Sie BFRI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BFRI Biofrontera Inc	0.813	7.21M	34.07M	-20.13M	-24.90M	-12.92
ZTS Zoetis Inc	163.11	73.07B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.05	47.43B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.24	45.72B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.08	17.28B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	306.97	14.37B	2.76B	1.11B	898.10M	22.77

Biofrontera Inc Aktie (BFRI) Neueste Nachrichten

Finanzdaten der Biofrontera Inc-Aktie (BFRI)

Biofrontera Inc (BFRI)

Biofrontera Inc Stock (BFRI) Company Profile

Vergleichen Sie BFRI mit anderen Aktien

Biofrontera Inc Aktie (BFRI) Neueste Nachrichten

Benchmark maintains Buy rating on Biofrontera stock, target at $7 By Investing.com - Investing.com Australia

Biofrontera Inc. (NASDAQ:BFRI) Q4 2024 Earnings Call Transcript - MSN

Biofrontera Inc. Reports Record Sales and Strategic Advances - MSN

Benchmark maintains Buy rating on Biofrontera stock, target at $7 - Investing.com India

Biofrontera outlines 2025 growth strategies with new FDA approvals and clinical progress - MSN

Biofrontera Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ... By GuruFocus - Investing.com Canada

Biofrontera Inc. Reports Record Revenue Growth in 2024 - TipRanks

Biofrontera Inc. reports Q4 EPS (19c) vs $1.65 last year - TipRanks

Earnings call transcript: Biofrontera Q4 2024 sees revenue growth and strategic shifts - Investing.com India

Biofrontera Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - TradingView

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - GlobeNewswire Inc.

Earnings Scheduled For March 21, 2025 - Benzinga

Biofrontera Inc. (BFRI) reports earnings - Quartz

Biofrontera Inc. SEC 10-K Report - TradingView

Biofrontera Completes Patient Enrollment for Phase 3 Trial of Ameluz in Actinic Keratoses - Marketscreener.com

Biofrontera completes patient enrollment in Phase 3 study of Ameluz - TipRanks

Biofrontera Inc. Announces Completion of Patient Enrollment - GlobeNewswire

Major Milestone: Biofrontera's Skin Cancer Treatment Targets New Body Areas in Phase 3 Trial - StockTitan

3 Reasons to Avoid KIND and 1 Stock to Buy Instead - The Globe and Mail

Biofrontera (BFRI) to Release Earnings on Friday - Defense World

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 - GlobeNewswire

BIOFRONTERA Earnings Preview: Recent $BFRI Insider Trading, Hedge Fund Activity, and More - Nasdaq

Dermatology Leader Biofrontera Sets Q4 Earnings Date: Key Growth Updates Expected - StockTitan

Biofrontera (BFRI) Projected to Post Earnings on Thursday - Defense World

Biofrontera Inc. (NASDAQ:BFRI) Short Interest Down 25.0% in February - Defense World

Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues - Simply Wall St

When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit? - Yahoo Finance

Biofrontera (NASDAQ:BFRI) Trading Down 3.5% – What’s Next? - Defense World

Constellation Brands: A Fallen Star or a Hidden Value Play? - The Globe and Mail

Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World

Biofrontera (NASDAQ:BFRI) vs. Sage Therapeutics (NASDAQ:SAGE) Critical Contrast - Defense World

Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts - ACCESS Newswire

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals - ACCESS Newswire

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024 - ACCESS Newswire

Biofrontera Inc. Announces Preliminary Third Quarter Revenues - ACCESS Newswire

Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study - TipRanks

Biofrontera Inc. Announces Achievement of Key Milestone In - GlobeNewswire

Biofrontera's Ameluz-PDT Skin Cancer Treatment Hits All Phase 3 Endpoints with Strong Results - StockTitan

Photonics IP Update: December 2024 - Laser Focus World

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - The Manila Times

Biofrontera Hits Major Milestone: 100th RhodoLED® XL Lamp Installed as PDT Treatment Demand Surges - StockTitan

Opendoor Technologies Inc (OPEN-Q) QuotePress Release - The Globe and Mail

Financial Contrast: Biofrontera (NASDAQ:BFRI) versus Amicus Therapeutics (NASDAQ:FOLD) - Defense World

Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga

Biofrontera Inc (BFRI:UR): Stock Price, Quote and News - BNN Bloomberg

Biofrontera to Present at Benchmark's Discovery Investor Conference in NYC - StockTitan

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Yahoo Finance

Biofrontera Inc. announced that it expects to receive $4.2 million in funding - Marketscreener.com

Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz

Finanzdaten der Biofrontera Inc-Aktie (BFRI)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie BFRI